TetraLogic Pharmaceuticals is a technology company.
TetraLogic Pharmaceuticals has raised $55.0M across 2 funding rounds.
TetraLogic Pharmaceuticals has raised $55.0M in total across 2 funding rounds.
TetraLogic Pharmaceuticals has raised $55.0M in total across 2 funding rounds.
TetraLogic Pharmaceuticals's investors include Hatteras Venture Partners.
TetraLogic Pharmaceuticals Corporation is a clinical-stage biopharmaceutical company headquartered in Malvern, Pennsylvania, specializing in the development of small molecule drugs.[1] It targets unmet medical needs through innovative therapies, primarily in areas like oncology and immunology, serving patients and healthcare providers by advancing candidates from preclinical stages to clinical trials.[1][2] Unlike typical technology companies focused on software or hardware, TetraLogic operates in biotech, solving complex biological problems with targeted small molecule compounds, though it lacks recent public data on current growth momentum, suggesting limited ongoing activity.[1][2]
TetraLogic Pharmaceuticals emerged as a biotech innovator in the clinical-stage development space, with its base in Malvern, Pennsylvania.[1] Specific details on founders or exact founding year are not detailed in available records, but the company gained visibility through its ticker TLOG on OTC markets, indicating a history tied to public trading and biopharma pipelines.[2] Pivotal moments likely centered on advancing small molecule programs into clinical trials, though the absence of recent updates points to a quieter evolution, possibly impacted by market delisting or acquisition dynamics common in biotech.[1][2]
TetraLogic rides the biotech wave within the broader life sciences ecosystem, where small molecule innovation intersects with advancing tech like AI-driven drug discovery and precision medicine. Its clinical-stage positioning aligns with market forces favoring therapies that address unmet needs in cancer and autoimmune diseases, amplified by regulatory shifts toward faster approvals. Though not a pure tech play, it contributes to the startup ecosystem by exemplifying how biopharma firms influence drug pipelines, potentially through partnerships or tech-enabled R&D tools, amid a landscape where biotech valuations hinge on trial outcomes and M&A activity.[1][2]
TetraLogic's path forward likely involves pipeline advancements or strategic exits, shaped by biotech trends like combo therapies and next-gen small molecules. Evolving influences could stem from renewed investor interest in undervalued clinical assets, but sparse recent data signals caution—watch for trial updates or OTC developments. This clinical-stage biotech underscores the high-stakes innovation defining biopharma's edge over traditional tech models.[1][2]
TetraLogic Pharmaceuticals has raised $55.0M across 2 funding rounds. Most recently, it raised $23.0M Series C in January 2011.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jan 1, 2011 | $23.0M Series C | Hatteras Venture Partners | |
| Aug 1, 2010 | $32.0M Series C | Hatteras Venture Partners |